APO RESEARCH · REPORT
Anti-inflammatory Therapeutics
Anti-inflammatory therapeutics are treatments for arthritis, respiratory diseases, dermatology, psoriasis, inflammatory bowel disease and other inflammatory diseases. The treatments include anti-inflammatory biologics, NSAIDs, corticosteroids and others.
Product & engineering
Understand the product.
Anti-inflammatory therapeutics are treatments for arthritis, respiratory diseases, dermatology, psoriasis, inflammatory bowel disease and other inflammatory diseases. The treatments include anti-inflammatory biologics, NSAIDs, corticosteroids and others.
Selected research
Market Analysis & Forecast
Global Anti-inflammatory Therapeutics Market Analysis and Forecast 2026-2032
Market perspective
Anti-inflammatory therapeutics are treatments for arthritis, respiratory diseases, dermatology, psoriasis, inflammatory bowel disease and other inflammatory diseases. The treatments include anti-inflammatory biologics, NSAIDs, corticosteroids and others.
Top 5 manufacturers make up the major market share in the anti-inflammatory therapeutics market. AbbVie maintained its first place in the ranking in 2019, accounted for 21.59% market share. Other players accounted for 14.20%, 5.43%, 5.32% including Johnson & Johnson, Amgen Inc, AstraZeneca PLC.
Report Includes
Read the full market overview
This report presents an overview of global market for Anti-inflammatory Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Anti-inflammatory Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Anti-inflammatory Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Anti-inflammatory Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anti-inflammatory Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Anti-inflammatory Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Anti-inflammatory Therapeutics Segment by Company
AbbVie
Johnson & Johnson
Amgen Inc
AstraZeneca PLC
Pfizer, Inc
Novartis
Roche
Merck
Sanofi
GlaxoSmithKline
Sun Pharmaceutical Industries Ltd
TEVA
Anti-inflammatory Therapeutics Segment by Type
Anti-inflammatory Biologics
Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Others
Anti-inflammatory Therapeutics Segment by Application
Arthritis
Respiratory Diseases
Dermatology
Gastroenterology
Others
Anti-inflammatory Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-inflammatory Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-inflammatory Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-inflammatory Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Anti-inflammatory Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Anti-inflammatory Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-inflammatory Therapeutics revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Anti-inflammatory Biologics
- Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
- Corticosteroids
- Others
Applications
- Arthritis
- Respiratory Diseases
- Dermatology
- Gastroenterology
- Others
Companies covered
- AbbVie
- Johnson & Johnson
- Amgen Inc
- AstraZeneca PLC
- Pfizer, Inc
- Novartis
- Roche
- Merck
- Sanofi
- GlaxoSmithKline
- Sun Pharmaceutical Industries Ltd
- TEVA
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Anti-inflammatory Therapeutics Market by Type
- 1.2.1 Global Anti-inflammatory Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Anti-inflammatory Biologics
- 1.2.3 Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
- 1.2.4 Corticosteroids
- 1.2.5 Others
- 1.3 Anti-inflammatory Therapeutics Market by Application
- 1.3.1 Global Anti-inflammatory Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Arthritis
- 1.3.3 Respiratory Diseases
- 1.3.4 Dermatology
- 1.3.5 Gastroenterology
- 1.3.6 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Anti-inflammatory Therapeutics Market Dynamics
- 2.1 Anti-inflammatory Therapeutics Industry Trends
- 2.2 Anti-inflammatory Therapeutics Industry Drivers
- 2.3 Anti-inflammatory Therapeutics Industry Opportunities and Challenges
- 2.4 Anti-inflammatory Therapeutics Industry Restraints
3 Global Growth Perspective
- 3.1 Global Anti-inflammatory Therapeutics Market Perspective (2021-2032)
- 3.2 Global Anti-inflammatory Therapeutics Growth Trends by Region
- 3.2.1 Global Anti-inflammatory Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Anti-inflammatory Therapeutics Market Size by Region (2021-2026)
- 3.2.3 Global Anti-inflammatory Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Anti-inflammatory Therapeutics Revenue by Players
- 4.1.1 Global Anti-inflammatory Therapeutics Revenue by Players (2021-2026)
- 4.1.2 Global Anti-inflammatory Therapeutics Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Anti-inflammatory Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Anti-inflammatory Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Anti-inflammatory Therapeutics Key Players Headquarters & Area Served
- 4.4 Global Anti-inflammatory Therapeutics Players, Product Type & Application
- 4.5 Global Anti-inflammatory Therapeutics Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Anti-inflammatory Therapeutics Market CR5 and HHI
- 4.6.3 2025 Anti-inflammatory Therapeutics Tier 1, Tier 2, and Tier 3
5 Anti-inflammatory Therapeutics Market Size by Type
- 5.1 Global Anti-inflammatory Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Anti-inflammatory Therapeutics Revenue by Type (2021-2032)
- 5.3 Global Anti-inflammatory Therapeutics Revenue Market Share by Type (2021-2032)
6 Anti-inflammatory Therapeutics Market Size by Application
- 6.1 Global Anti-inflammatory Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Anti-inflammatory Therapeutics Revenue by Application (2021-2032)
- 6.3 Global Anti-inflammatory Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 AbbVie
- 7.1.1 AbbVie Company Information
- 7.1.2 AbbVie Business Overview
- 7.1.3 AbbVie Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
- 7.1.4 AbbVie Anti-inflammatory Therapeutics Product Portfolio
- 7.1.5 AbbVie Recent Developments
- 7.2 Johnson & Johnson
- 7.2.1 Johnson & Johnson Company Information
- 7.2.2 Johnson & Johnson Business Overview
- 7.2.3 Johnson & Johnson Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
- 7.2.4 Johnson & Johnson Anti-inflammatory Therapeutics Product Portfolio
- 7.2.5 Johnson & Johnson Recent Developments
- 7.3 Amgen Inc
- 7.3.1 Amgen Inc Company Information
- 7.3.2 Amgen Inc Business Overview
- 7.3.3 Amgen Inc Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
- 7.3.4 Amgen Inc Anti-inflammatory Therapeutics Product Portfolio
- 7.3.5 Amgen Inc Recent Developments
- 7.4 AstraZeneca PLC
- 7.4.1 AstraZeneca PLC Company Information
- 7.4.2 AstraZeneca PLC Business Overview
- 7.4.3 AstraZeneca PLC Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
- 7.4.4 AstraZeneca PLC Anti-inflammatory Therapeutics Product Portfolio
- 7.4.5 AstraZeneca PLC Recent Developments
- 7.5 Pfizer, Inc
- 7.5.1 Pfizer, Inc Company Information
- 7.5.2 Pfizer, Inc Business Overview
- 7.5.3 Pfizer, Inc Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
- 7.5.4 Pfizer, Inc Anti-inflammatory Therapeutics Product Portfolio
- 7.5.5 Pfizer, Inc Recent Developments
- 7.6 Novartis
- 7.6.1 Novartis Company Information
- 7.6.2 Novartis Business Overview
- 7.6.3 Novartis Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
- 7.6.4 Novartis Anti-inflammatory Therapeutics Product Portfolio
- 7.6.5 Novartis Recent Developments
- 7.7 Roche
- 7.7.1 Roche Company Information
- 7.7.2 Roche Business Overview
- 7.7.3 Roche Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
- 7.7.4 Roche Anti-inflammatory Therapeutics Product Portfolio
- 7.7.5 Roche Recent Developments
- 7.8 Merck
- 7.8.1 Merck Company Information
- 7.8.2 Merck Business Overview
- 7.8.3 Merck Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
- 7.8.4 Merck Anti-inflammatory Therapeutics Product Portfolio
- 7.8.5 Merck Recent Developments
- 7.9 Sanofi
- 7.9.1 Sanofi Company Information
- 7.9.2 Sanofi Business Overview
- 7.9.3 Sanofi Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
- 7.9.4 Sanofi Anti-inflammatory Therapeutics Product Portfolio
- 7.9.5 Sanofi Recent Developments
- 7.10 GlaxoSmithKline
- 7.10.1 GlaxoSmithKline Company Information
- 7.10.2 GlaxoSmithKline Business Overview
- 7.10.3 GlaxoSmithKline Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
- 7.10.4 GlaxoSmithKline Anti-inflammatory Therapeutics Product Portfolio
- 7.10.5 GlaxoSmithKline Recent Developments
- 7.11 Sun Pharmaceutical Industries Ltd
- 7.11.1 Sun Pharmaceutical Industries Ltd Company Information
- 7.11.2 Sun Pharmaceutical Industries Ltd Business Overview
- 7.11.3 Sun Pharmaceutical Industries Ltd Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
- 7.11.4 Sun Pharmaceutical Industries Ltd Anti-inflammatory Therapeutics Product Portfolio
- 7.11.5 Sun Pharmaceutical Industries Ltd Recent Developments
- 7.12 TEVA
- 7.12.1 TEVA Company Information
- 7.12.2 TEVA Business Overview
- 7.12.3 TEVA Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
- 7.12.4 TEVA Anti-inflammatory Therapeutics Product Portfolio
- 7.12.5 TEVA Recent Developments
8 North America
- 8.1 North America Anti-inflammatory Therapeutics Revenue (2021-2032)
- 8.2 North America Anti-inflammatory Therapeutics Revenue by Type (2021-2032)
- 8.2.1 North America Anti-inflammatory Therapeutics Revenue by Type (2021-2026)
- 8.2.2 North America Anti-inflammatory Therapeutics Revenue by Type (2027-2032)
- 8.3 North America Anti-inflammatory Therapeutics Revenue Share by Type (2021-2032)
- 8.4 North America Anti-inflammatory Therapeutics Revenue by Application (2021-2032)
- 8.4.1 North America Anti-inflammatory Therapeutics Revenue by Application (2021-2026)
- 8.4.2 North America Anti-inflammatory Therapeutics Revenue by Application (2027-2032)
- 8.5 North America Anti-inflammatory Therapeutics Revenue Share by Application (2021-2032)
- 8.6 North America Anti-inflammatory Therapeutics Revenue by Country
- 8.6.1 North America Anti-inflammatory Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Anti-inflammatory Therapeutics Revenue by Country (2021-2026)
- 8.6.3 North America Anti-inflammatory Therapeutics Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Anti-inflammatory Therapeutics Revenue (2021-2032)
- 9.2 Europe Anti-inflammatory Therapeutics Revenue by Type (2021-2032)
- 9.2.1 Europe Anti-inflammatory Therapeutics Revenue by Type (2021-2026)
- 9.2.2 Europe Anti-inflammatory Therapeutics Revenue by Type (2027-2032)
- 9.3 Europe Anti-inflammatory Therapeutics Revenue Share by Type (2021-2032)
- 9.4 Europe Anti-inflammatory Therapeutics Revenue by Application (2021-2032)
- 9.4.1 Europe Anti-inflammatory Therapeutics Revenue by Application (2021-2026)
- 9.4.2 Europe Anti-inflammatory Therapeutics Revenue by Application (2027-2032)
- 9.5 Europe Anti-inflammatory Therapeutics Revenue Share by Application (2021-2032)
- 9.6 Europe Anti-inflammatory Therapeutics Revenue by Country
- 9.6.1 Europe Anti-inflammatory Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Anti-inflammatory Therapeutics Revenue by Country (2021-2026)
- 9.6.3 Europe Anti-inflammatory Therapeutics Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Anti-inflammatory Therapeutics Revenue (2021-2032)
- 10.2 China Anti-inflammatory Therapeutics Revenue by Type (2021-2032)
- 10.2.1 China Anti-inflammatory Therapeutics Revenue by Type (2021-2026)
- 10.2.2 China Anti-inflammatory Therapeutics Revenue by Type (2027-2032)
- 10.3 China Anti-inflammatory Therapeutics Revenue Share by Type (2021-2032)
- 10.4 China Anti-inflammatory Therapeutics Revenue by Application (2021-2032)
- 10.4.1 China Anti-inflammatory Therapeutics Revenue by Application (2021-2026)
- 10.4.2 China Anti-inflammatory Therapeutics Revenue by Application (2027-2032)
- 10.5 China Anti-inflammatory Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Anti-inflammatory Therapeutics Revenue (2021-2032)
- 11.2 Asia Anti-inflammatory Therapeutics Revenue by Type (2021-2032)
- 11.2.1 Asia Anti-inflammatory Therapeutics Revenue by Type (2021-2026)
- 11.2.2 Asia Anti-inflammatory Therapeutics Revenue by Type (2027-2032)
- 11.3 Asia Anti-inflammatory Therapeutics Revenue Share by Type (2021-2032)
- 11.4 Asia Anti-inflammatory Therapeutics Revenue by Application (2021-2032)
- 11.4.1 Asia Anti-inflammatory Therapeutics Revenue by Application (2021-2026)
- 11.4.2 Asia Anti-inflammatory Therapeutics Revenue by Application (2027-2032)
- 11.5 Asia Anti-inflammatory Therapeutics Revenue Share by Application (2021-2032)
- 11.6 Asia Anti-inflammatory Therapeutics Revenue by Country
- 11.6.1 Asia Anti-inflammatory Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Anti-inflammatory Therapeutics Revenue by Country (2021-2026)
- 11.6.3 Asia Anti-inflammatory Therapeutics Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Anti-inflammatory Therapeutics Revenue (2021-2032)
- 12.2 SAMEA Anti-inflammatory Therapeutics Revenue by Type (2021-2032)
- 12.2.1 SAMEA Anti-inflammatory Therapeutics Revenue by Type (2021-2026)
- 12.2.2 SAMEA Anti-inflammatory Therapeutics Revenue by Type (2027-2032)
- 12.3 SAMEA Anti-inflammatory Therapeutics Revenue Share by Type (2021-2032)
- 12.4 SAMEA Anti-inflammatory Therapeutics Revenue by Application (2021-2032)
- 12.4.1 SAMEA Anti-inflammatory Therapeutics Revenue by Application (2021-2026)
- 12.4.2 SAMEA Anti-inflammatory Therapeutics Revenue by Application (2027-2032)
- 12.5 SAMEA Anti-inflammatory Therapeutics Revenue Share by Application (2021-2032)
- 12.6 SAMEA Anti-inflammatory Therapeutics Revenue by Country
- 12.6.1 SAMEA Anti-inflammatory Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Anti-inflammatory Therapeutics Revenue by Country (2021-2026)
- 12.6.3 SAMEA Anti-inflammatory Therapeutics Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst